Boston, MA-- A new study finds that the diabetes drug liraglutide leads to weight loss by acting on an area of the brain that controls attention and possibly making desirable foods less rewarding. Researchers will present their results Saturday at the Endocrine Society's 98th annual meeting in Boston.
"Our finding suggests liraglutide may make people more attentive to what they are eating, particularly high-calorie or high-fat foods," said study co-investigator Olivia Farr, PhD, an Instructor in Medicine at Beth Israel Deaconess Medical Center and Harvard Medical School, Boston.
Injectable liraglutide is an analog, or mimicker, of the glucagon-like peptide (GLP) hormone in the body that controls metabolism and appetite. Used at 1.8-milligram doses, liraglutide (brand name Victoza) can cause weight loss in people with Type 2 diabetes. A 3-milligram dose is marketed as Saxenda for weight management in overweight or obese people without diabetes. Although researchers suspected liraglutide may work directly in the brain to decrease weight based on animal studies, Farr said how or where in the human brain the drug acted was unclear.
In a preliminary study, Farr and her colleagues in the Mantzoros laboratory used immunohistochemistry to analyze 22 human brain tissue samples for the presence of GLP-1 receptors, which are protein molecules that respond to the GLP hormone's signal. She said they found--for the first time--that GLP-1 is expressed in the human brain. They reportedly saw evidence of this expression on neurons, or nerve cells, in the cerebral cortex of the forebrain, an area responsible for higher thought.
The researchers performed a second study in 18 adults with Type 2 diabetes. Participants received 17 days of either liraglutide, up to 1.8 milligrams, or a placebo (dummy drug) in a random order. Then after a three-week "washout" of no medication, the same participants received 17 days of the opposite treatment. Participants were unaware which treatment they received.
On day 17 of each treatment, participants underwent brain scanning with functional magnetic resonance imaging (fMRI). During fMRI, participants viewed images of different foods. In response to highly desirable foods such as cake, pastries and fried foods, liraglutide decreased reward activations in the cortex compared with images of less desirable foods, such as fruits, vegetables and other low-calorie, low-fat foods, the investigators reported.
"This decreased activation means that individuals on liraglutide find highly desirable foods less attention-grabbing and less rewarding than they typically would without liraglutide," Farr said. "Thus, this medication may prove to be better for weight loss for people who tend to eat more high-fat food as a reward, such as when they are stressed. Our study identifies neural targets for more effective weight loss therapeutics in the future."
Farr said they are planning more studies to uncover whether they obtain the same results with the higher liraglutide dose approved for weight management. Additionally, they hope to discover whether there are individual differences in terms of the brain's response to liraglutide and whether any compensatory brain activations may arise at higher doses to curb weight loss.
The study received funding from the National Institutes of Health and Novo Nordisk, the manufacturer of liraglutide.
Endocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers. The Endocrine Society is the world's oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions.
The Society, which is celebrating its centennial in 2016, has more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries. To learn more about the Society and the field of endocrinology, visit our site at http://www.endocrine.org. Follow us on Twitter at @TheEndoSociety and @EndoMedia.